NCT01306942View on ClinicalTrials.gov

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

March 15, 2019

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Dasatinib

DRUG

Trastuzumab

DRUG

Paclitaxel

Trial Locations (8)

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

28007

Hospital General Universitario Gregorio Marañón, Madrid

29010

Hospital Clínico Universitario Virgen de la Victoria, Málaga

36204

Hospital Alvaro Cunqueiro, Vigo

41013

Hospital Universitario Virgen del Rocío, Seville

46009

Instituto Valenciano de Oncología, Valencia

08907

Instituto Catalán de Oncología de Barcelona (Hospital Duran i Reynalds), L'Hospitalet de Llobregat

08036

Hospital Clinic i Provincial, Barcelona

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER